KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study.

Rosario Pivonello, Giorgio Arnaldi, Richard J Auchus, Corin Badiu, Robert S Busch, Salvatore Cannavò, Ulrich Dischinger, Georgiana A Dobri, Diane M Donegan, Atanaska Elenkova, Pouneh K Fazeli, Richard A Feelders, Rogelio Garcia-Centeno, Aleksandra Gilis-Januszewska, Oksana Hamidi, Zeina C Hannoush, Atil Y Kargi, Harold J Miller, Aurelian-Emil Ranetti, Monica Recasens, Martin Reincke, Sergio Rovner, Roberto Salvatori, Julie Silverstein, Antonio Stigliano, Massimo Terzolo, Christina Wang, Kevin C J Yuen, Amanda Kesner-Hays, Austin L Hand, Iulia Cristina Tudor, Katherine A Araque, Andreas G Moraitis, GRACE Study Investigators

Lancet Diabetes Endocrinol 14(4) 291-304

PMID41730814
PMCIDPMC13220893
DOI10.1016/S2213-8587(25)00362-6
发表日期2026-02-23
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:身体组成变化图。
摘要

摘要

BACKGROUND: Relacorilant is a selective glucocorticoid receptor modulator designed to reduce excess cortisol activity by competing with cortisol for glucocorticoid receptor binding, mitigating the clinical manifestations of endogenous hypercortisolism (Cushing's syndrome). The aim of this study was to assess the efficacy and safety of relacorilant in adults with endogenous hypercortisolism. METHODS: This multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study enrolled adults with endogenous hypercortisolism and hypertension, hyperglycaemia, or both and was conducted at 77 study centres across 11 countries. Key inclusion criteria included being aged 18-80 years with at least two clinical signs or symptoms of hypercortisolism. In the open-label phase, patients received oral, once-daily relacorilant (escalation from 100 mg up to 400 mg) for 22 weeks. Patients who met response criteria were randomly assigned (1:1) by the interactive web response system to continue relacorilant 400 mg (or highest tolerated dose) or placebo for 12 weeks in the randomised-withdrawal phase. Participants and investigators were masked to treatment assignment. The primary outcome was the proportion of patients who lost hypertension response during the randomised-withdrawal phase compared between relacorilant and placebo at week 12. As per protocol, this outcome was assessed in all participants who received at least one dose of study drug in the study period (intention-to-treat population). Missing randomised-withdrawal week 12 values were considered a loss of response. Safety was assessed in all enrolled patients who received at least one dose of study drug in that period. This study is registered with ClinicalTrials.gov, NCT03697109. FINDINGS: Between Oct 16, 2018, and April 15, 2024, 404 patients were screened, 152 were enrolled, and 95 completed the open-label relacorilant phase. 62 patients met response criteria and were randomly assigned to relacorilant (30 total participants [21 met hypertension response criteria]) or placebo (32 total participants [22 met hypertension response criteria]). In the 30 participants in the relacorilant group, the mean age was 46·6 years (SD 11·0), 22 (73%) were female, and eight (27%) were male. In the 32 participants in the placebo group, the mean age was 48·8 years (SD 14·4), 26 (81%) were female, and six (19%) were male. During the randomised-withdrawal phase, significantly more patients with baseline hypertension who were randomly assigned to placebo lost hypertension control compared with those who continued relacorilant (proportion difference 34%; odds ratio 0·17 [95% CI 0·04-0·77]; p=0·022). In the randomised-withdrawal phase safety population, the most common adverse events in the 30 participants given relacorilant and the 32 participants given placebo were back pain (5 [17%] vs 6 [19%]), acne (3 [10%] vs 0), arthralgia (3 [10%] vs 3 [9%]), bursitis (3 [10%] vs 0), headache (3 [10%] vs 4 [13%]), and insomnia (0 vs 4 [13%]). There were no cases of excessive glucocorticoid receptor antagonism, adrenal insufficiency, vaginal bleeding associated with endometrial hypertrophy, drug-induced hypokalaemia, or drug-induced QT interval prolongation. INTERPRETATION: Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic option to reduce the harmful and debilitating effects of endogenous hypercortisolism. FUNDING: Corcept Therapeutics.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1:. Study profile ITT=intention-to-treat. *Two patients were erroneously characterised in the electronic case report form as having met response criteria and entered the randomised-withdrawal phase. †Three people excluded due to not having at least one post-randomisation efficacy assessment for the primary efficacy endpoint. ‡Seven people excluded due to important protocol deviations (three due to mis-stratification, one due to missing week 12 visit, one due to missing AMBP and study drug compliance, one due to concomitant medications, and one due to missing post-randomisation efficacy assessment for the primary efficacy endpoint). §Four people excluded due to not having at least one post-randomisation efficacy assessment for the primary efficacy endpoint. ¶Four people excluded due to important protocol deviations (two due to mis-stratification and two due to missing post-randomisation efficacy assessment for the primary efficacy endpoint).
非 KM Figure
Figure 2Figure 2:. Least squares mean difference between relacorilant and placebo at randomised-withdrawal week 12 for blood pressure and glycaemia Change in blood pressure (SBP and DBP; A), OGTT plasma glucose (B), and HbA 1c (C). DBP=diastolic blood pressure. LSM=least squares mean. OGTT=oral glucose tolerance test. SBP=systolic blood pressure.
非 KM Figure
Figure 3Figure 3:. Least squares mean difference between relacorilant and placebo at randomised-withdrawal week 12 for body composition Change in mean weight (A), waist circumference (B), tissue fat mass (C), and tissue lean mass (D). LSM=least squares mean.
非 KM Figure